Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma

Share :
Published: 16 Jun 2018
Views: 1557
Rating:
Save
Dr Ramon Garcia Sanz - Hospital Universitario de Salamanca, Salamanca, Spain

Dr Garcia-Sanz speaks with ecancer at EHA 23 about the results from a phase I/II trial of treating r/rHL with brentuximab vedotin, along with ESHAP chemo, to improve depth of response ahead of stem cell transplant.

He describes the tolerability of the combination as easily managed, and the overall pre transplant response as 93% including a 71% complete response rate.

Dr Garcia-Sanz highlights these findings are now leading to a phase III trial, with the combination highly effective at inducing remission before transplant.